Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for treatment resistant depression therapy, AstraZeneca/Targacept's TC-5214 will earn Decision Resources' proprietary clinical gold standard status in 2013 (following its approval that year) and through 2018. Phase IIb trial results show significant improvement in Hamilton Depression Rating Scale scores on the effect on depressive symptoms in patients who did not respond adequately to citalopram monotherapy. These results indicate that TC-5214 has competitive advantages in efficacy over current and emerging drugs for treatment resistant depression.
"Phase IIb trials demonstrated the efficacy of TC-5214 as an augmentation therapy for major depressive disorder; should Phase III trials demonstrate both efficacy and tolerability, TC-5214 will have a significant market advantage and may earn blockbuster sales in the major depressive disorder market," stated Decision Resources' Analyst Alana Simorellis, Ph.D.
The new report entitled Major Depressive Disorder (Treatment Resistant): Incremental Efficacy Improvements Are a Key Area of Differentiation in This Mature Market finds that effect on depressive symptoms is the most important drug attribute surveyed European and U.S. psychiatrists consider when prescribing a drug for treatment resistant depression. Surveyed European and U.S. psychiatrists also indicated that though they are not willing to compromise on safety and tolerability for a new emerging drug they also do not require significant improvements.
"Psychiatrists we surveyed indicated that an emerging agent with a safety and tolerability profile similar to that of AstraZeneca's Seroquel XR, coupled with modest improvements in certain efficacy end points relative to Seroquel XR, would gain significant traction in the treatment resistant subpopulation of the major depressive disorder drug market," added Dr. Simorellis.
About the Report
Major Depressive Disorder (Treatment Resistant): Incremental Efficacy Improvements Are a Key Area of Differentiation in This Mature Market is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.
About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources, Inc. Christopher Comfort 781-296-2597 email@example.com
First Call Analyst:
SOURCE: Decision Resources
CONTACT: Decision Resources, Inc., Christopher Comfort, +1-781-296-2597,
Web Site: http://www.decisionresources.com/